Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

7043834

Reference Type

Journal Article

Title

Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study

Author(s)

Farnier, M; Steinmetz, A; Retterstøl, K; Császár, A; ,

Year

2011

Is Peer Reviewed?

Yes

Journal

Clinical Therapeutics
ISSN: 0149-2918

Publisher

ELSEVIER

Location

BRIDGEWATER

Page Numbers

1-12

Language

English

PMID

21397769

DOI

10.1016/j.clinthera.2011.02.006

Web of Science Id

WOS:000288924800001

Abstract

Patients with type 2 diabetes mellitus and mixed hyperlipidemia have an increased cardiovascular risk and may not achieve recommended LDL-C and non-HDL-C goals on statin monotherapy. This study was designed to obtain regulatory approval of a fenofibrate/pravastatin 160/40 mg fixed-dose combination (FDC) capsule.